We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Agentic AI Platform Supports Genomic Decision-Making in Oncology

By LabMedica International staff writers
Posted on 01 Jun 2026

Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. More...

Translating multimodal data into patient-specific, point-of-care guidance remains difficult within routine clinical workflows. To address this gap, a newly upgraded physician platform now embeds next-generation agentic artificial intelligence (AI) to proactively surface genomic insights and generate patient-ready documentation, aiming to streamline decision support in oncology care.

Tempus AI (Chicago, IL, USA) has upgraded its AI-enabled smart physician platform, Tempus Hub, by embedding a next-generation generative AI clinical co-pilot that delivers an agent-first experience for healthcare providers. The upgrade connects the company’s advanced agentic AI directly with real-time patient data within Hub, aligning large language model capabilities with each patient’s diagnostic results to support cancer care decisions. Hub is a secure platform used by thousands of oncologists and care teams to deliver actionable insights at the point of care.

Within Hub, clinicians can access Tempus test orders and results, including guideline-matched therapies, treatment resistance insights, clinical trial opportunities, and longitudinal biomarker tracking for every patient. The new architecture adds proactive, agentic AI that can automatically produce patient overviews and apply deeper analysis to a patient’s Tempus genomic results on the summary page. It also expands into next-step documentation generation, enabling instant creation of patient-specific materials such as prior authorizations and patient messages by pulling directly from Tempus data.

These capabilities are supported by foundational connectivity layers: Edge, which enables real-time connections to electronic health record (EHR) systems and other provider platforms; Locker, which allows providers to store data in a secure, provider‑controlled environment; and Air, which deploys AI models and algorithms in real time at the point of care. Planned iterations include linking Tempus genomics results with the company’s longitudinal patient registry or health information exchange (HIE) data to enable more complex generative AI workflows. Together, these additions are intended to scale how providers utilize, interpret, and act on complex diagnostic insights during routine encounters.

“Our evolution toward an agent-first experience within the Tempus Hub represents a massive win for clinical workflow efficiency,” said Shane Colley, Chief Technology Officer at Tempus. “By bringing our most sophisticated co-pilot intelligence directly into the Hub, we are unlocking the true power of multimodal data to provide seamless, on-demand decision support that meets providers exactly where they are."

Related Links
Tempus AI


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.